Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Artivion, Inc. AORT

Healthcare  —  Medical Devices
22.63 (0.40) (1.74%) as of 25 Sep
Market cap
$1.1B
P/E
0.0×
Dividend Champion (3y) Cash Flow Champion (3y) Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Artivion, Inc. (AORT) Business Profile

Updated before January 2025

Company Overview

Artivion, Inc. (AORT), formerly known as CryoLife, Inc., is a leading medical device company specializing in the development, manufacturing, and distribution of innovative technologies for the treatment of cardiovascular and vascular diseases. Founded in 1984 and headquartered in Kennesaw, Georgia, Artivion has established itself as a global leader in the medical device industry. The company underwent a rebranding in 2021 to reflect its commitment to advancing the art of medical innovation. Artivion is led by a team of experienced executives, including CEO Pat Mackin, who has been instrumental in driving the company’s strategic growth and innovation.

Core Business Segments

Artivion operates across several core business segments, each focused on addressing critical medical needs in the cardiovascular and vascular space. These segments include:

1. Aortic Repair

Artivion offers a range of products designed to treat aortic diseases, including aneurysms and dissections. Key products in this category include:

  • E-vita Open NEO: A hybrid stent graft system for the treatment of complex aortic arch diseases.
  • NEXUS Aortic Arch Stent Graft System: A cutting-edge solution for minimally invasive aortic arch repair.

2. Heart Valve Replacement and Repair

The company provides innovative solutions for heart valve replacement and repair, including:

  • On-X Mechanical Heart Valve: Known for its durability and reduced need for anticoagulation therapy.
  • CryoValve SG Pulmonary Valve: A cryopreserved human heart valve used in reconstructive surgeries.

3. Tissue Processing and Preservation

Artivion is a pioneer in tissue processing and preservation technologies, offering:

  • CryoLife Tissue Processing: A proprietary method for preserving human cardiac and vascular tissues.
  • BioGlue Surgical Adhesive: A versatile adhesive used in cardiovascular and general surgical procedures.

4. Vascular Surgery

The company also provides products for vascular surgery, including grafts and patches for peripheral vascular disease treatment.

Business Model

Artivion’s business model is centered on innovation, quality, and patient outcomes. The company integrates its products and services by leveraging its proprietary technologies and expertise in tissue preservation and medical device manufacturing. Revenue is generated through the sale of medical devices, tissue processing services, and licensing agreements. Artivion also invests heavily in research and development to maintain its competitive edge and expand its product portfolio.

Strategic Direction

Artivion is focused on achieving sustainable growth through innovation and global expansion. Key strategic initiatives include:

  • Product Development: Continued investment in R&D to develop next-generation medical devices and expand its product offerings.
  • Global Expansion: Strengthening its presence in international markets, particularly in Europe and Asia.
  • Sustainability Goals: Implementing environmentally friendly practices in manufacturing and operations.
  • Mergers and Acquisitions: Exploring strategic acquisitions to enhance its capabilities and market reach.

Competitive Landscape

Artivion operates in a highly competitive industry, facing competition from both large multinational corporations and specialized medical device companies. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of cardiovascular products.
  • Edwards Lifesciences: Known for its innovative heart valve technologies.
  • Terumo Corporation: A major player in the vascular and cardiovascular device market.
  • Abbott Laboratories: Offers a diverse portfolio of cardiovascular and vascular products.

Risk Factors

Artivion faces several risks that could impact its operations and financial performance, including:

  • Market Dependence: Reliance on a limited number of products for a significant portion of revenue.
  • Regulatory Challenges: Stringent regulatory requirements for medical device approval and compliance.
  • Supply Chain Disruptions: Potential disruptions in the supply of raw materials and components.
  • Competition: Intense competition from established players and new market entrants.

Recent Developments

Artivion has made significant strides in recent years, including:

  • Launch of NEXUS Aortic Arch Stent Graft System: A major milestone in minimally invasive aortic repair.
  • Rebranding to Artivion: Reflecting its commitment to innovation and growth.
  • Expansion in Europe: Strengthening its distribution network and regulatory approvals in key European markets.
  • COVID-19 Impact: Navigating challenges posed by the pandemic, including supply chain disruptions and changes in surgical procedures.

Investment Considerations

Investors considering Artivion should weigh the following strengths and risks:

Strengths

  • Strong product portfolio with innovative technologies.
  • Established global presence and distribution network.
  • Commitment to R&D and product innovation.
  • Experienced leadership team.

Risks

  • Dependence on a few key products for revenue.
  • Exposure to regulatory and compliance risks.
  • Vulnerability to economic and healthcare industry fluctuations.

Conclusion

Artivion, Inc. is a dynamic and innovative company at the forefront of cardiovascular and vascular medical technologies. With a strong product portfolio, strategic growth initiatives, and a commitment to improving patient outcomes, Artivion is well-positioned for long-term success. However, investors should carefully consider the associated risks and market dynamics before making investment decisions.